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Engrailed (En) is a member of the homeobox gene family, which encodes a homeodomain-contain-
ing transcription factor that is essential during early development. The only known site of normal
adult Engrailed protein (EN) expression is in the nervous system, and it has been implicated in
the development of both young-onset Parkinson’s disease as well as autism. Over-expression of
EN has been linked to tumour development in adults, particularly in breast, prostate, melanoma
and ovarian cancers, and there is a growing interest in its role as a diagnostic and prognostic bio-
marker. It is hoped that further work may conﬁrm associations between En expression and ther-
apy-resistant, poor prognosis cancers, similar to that identiﬁed with other homeobox gene proﬁles.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. Open access under 1. Introduction
The homeobox genes are a superfamily of regulatory genes that
encode homeodomain-containing transcription factors. They play a
key role in early embryonic development but have also been linked
to disease, including cancer. This review will aim to give an over-
view of homeobox gene function, particularly focusing on the biol-
ogy of Engrailed (En), its role in disease including malignancy, and
its potential as a biomarker.
The homeobox refers to a 183-bp DNA sequence, originally
identiﬁed in Drosophila, which encodes a 61-amino-acid homeodo-
main within HOX proteins, enabling recognition and binding of se-
quence-speciﬁc DNA motifs. The speciﬁcity of this binding allows
the protein to activate or repress the expression of many down-
stream effector target genes [1].
Over 100 homeobox genes have been identiﬁed, all of which
share sequence similarity within the homeodomains, and have
been separated into individual groups such as the HOX gene, the
paired (PAX) gene, and the Engrailed (En) gene families. It is cur-rently thought that homeobox genes represent 0.1–0.2% of the en-
tire vertebrate genome. The role of homeobox-containing genes has
been reported in vertebrate embryonic development. Speciﬁcally,
they have been shown to be involved in the control of cell identity,
cell growth and differentiation, as well as cell–cell and cell–extra-
cellular matrix interactions. In mammals this extends to central
nervous system, skeletal and limb development, as well as organo-
genesis. Many genetic disorders have been associated with deregu-
lation of the homeobox genes, affecting multiple organ systems,
and this can involve an up- or down-regulation of expression [2].
Analysis of the homeobox gene abnormalities has demonstrated
the presence of deletion, insertion and substitution mutations.
Thirty-nine HOX genes have been identiﬁed in humans and are
implicated in apoptosis, receptor signalling, differentiation, motil-
ity and angiogenesis [2]. They are fundamental to normal limb
and organ development along the anterior–posterior axis [3], as
well as blood vessel formation and prostate gland development
[4]. In the normal adult human, speciﬁc patterns of HOX gene
expression are involved in stem cell function as well as haemato-
poietic lineage differentiation, particularly the HOXA10, HOXB3
and HOXC4 genes [5]. In addition, expression of HOXA10 and
HOXA11 varies during the course of the human menstrual cycle,
with the most drastic increase occurring at the time of implanta-
tion. This continual process mirrors the HOX gene expression seen
in the developing reproductive tract [6].
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mental limb malformations such as synpolydactyly (HOXD13) [7],
radio-ulnar synostosis (HOXA11) [8] and the hand-foot-genital syn-
drome (HOXA13) [9], as well as malignancy. The HOXA9 gene is
associated with a form of acute myeloid leukaemia [10], and cer-
tain lymphoblastic leukaemias, and confers a worse prognosis
and treatment failure [11]. HOXC4–6 are expressed in non-
Hodgkin’s lymphomas [12]. The HOX gene family have also been
implicated in the development of kidney tumours (HOXA9,
-C9, -D10) [13], colon (HOXA9, -B6–8, -C8–9, -D11) [14], lung
(HOXA1,-A7, -A9, -C5) [15], breast (HOXA5, -A10, -B7, -B13) [16],
prostate (HOXB13, -C8) [17,18], melanoma (HOXB7) [19,20],
endometrial (HOXD10) [21] and ovarian cancers (HOXA7, -A9–11,
-B13) [22,23]. Certain gene expression proﬁles are associated with
therapy-resistant cancers, and an increased risk of distant metasta-
sis at recurrence [24].
Genetic control of the vertebrate anterior head and rostral brain
development is inﬂuenced by Emx and Otx genes, with
heterozygous mutations in the human EMX2 gene contributing to
schizencephaly, a rare congenital brain malformation accompanied
by craniofacial defects [25]. TheMSX gene family are closely linked
with craniofacial and tooth development and MSX2 has been
implicated in melanoma cell invasion and survival, with cytoplas-
mic expression indicating improved prognosis [26].
PAX genes are mostly involved in the control of embryonic tis-
sue development and cellular differentiation, including renal mor-
phogenesis (PAX2, -8), B-lymphocyte differentiation (PAX5), and
central nervous system development. They show a strong correla-
tion with human diseases, in particular renal defects and Wilms’
tumours (PAX2, -8), microcephaly (PAX6), glioblastoma multiforme
(PAX5), rhabdomyosarcoma (PAX3), congenital cataracts and other
eye defects (PAX6), prostate cancer (PAX2) and thyroid cancers
(PAX8) [27].
2. The biology of Engrailed
Engrailed (En) is another member of the homeobox gene family,
which was ﬁrst characterised in Drosophila. The encoded homeodo-
main-containing transcription factor again plays an important role
in development, and has been identiﬁed in annelids [28], molluscs
[29], insects [30], echinoderms, chordates [31], and vertebrates
[32]. Although these genes share a limited degree of sequence con-
servation at the protein level, there are ﬁve En homology regions
(EHs) which represent particular regions of similarity [33]
(Fig. 1). Tolkunova et al. demonstrated that EH1 mediates tran-
scriptional repression by recruiting the co-repressor groucho, and
EH5 has a similar role [34]. EH4 is the homeodomain, which dem-
onstrates the highest level of conservation [33], whilst EH2 and
EH3 bind PBX, another homeodomain-containing transcription fac-
tor. The latter is able to modify the DNA binding afﬁnity and
speciﬁcity of En [35,36]. In addition to transcription, En protein
may have a regulatory role in translation, as it is able to bindFig. 1. Functional domainsdirectly to the eukaryotic translation initiation factor 4E (eIF4E)
with high afﬁnity and speciﬁcity [37].
The homeodomain sequences also facilitate the association of
cytoplasmic En protein with vesicles, enabling secretion of the pro-
tein from the cell [38–40]. En can also undergo internalization by
the cell, a mechanism dependent upon sequences within the
homeodomain [41]. This process has been demonstrated both at
4 and 37 C and does not appear to require a speciﬁc receptor,
although both the secretion and internalization mechanisms have
yet to be fully elucidated [42,43].
Following its identiﬁcation in Drosophila, where the mutated En
resulted in a malformation of the border between the posterior and
anterior wing compartments [44], further evaluation of its role in
embryological neural and axonal development has taken place. In
vertebrates, two En genes were discovered, En1 and En2, which dif-
fer slightly in their speciﬁc functions [45,46]. High levels of both
En1 and En2 are expressed in the alar (dorsal) cells of the mid-
brain/hindbrain border region during brain development, and
inﬂuence the survival of mesencephalic dopaminergic neurons
[47–50]. Wilson et al. recently demonstrated that En1 and En2
are expressed in many cell types in the cerebellum, with expres-
sion still evident at postnatal day 21 [51]. Between this point and
the embryonic stages, there is a distinct change in their cellular
and spatial distributions, with the expression domains becoming
distinct. En plays a pivotal role in axonal guidance, as demon-
strated in the developing chick optic tectum [52], where En2 helps
to establish rostro-caudal polarity. The EN2 protein continues to
exert its actions even after internalization by the axons [53]. The
En2 gene has also been implicated in early muscle development,
with expression in the murine mandibular arch myoblasts in par-
ticular, which give rise to the masseter, temporalis, and lateral
and medial pterygoid muscles involved in jaw closure [54]. Germ-
line mutations in En are therefore likely to have profound effects
on embryological development.
Expression of En genes in the human foetus has been demon-
strated in all of the neuronal groups of the mid-gestational medulla
and cerebellum, and is thought to be crucially involved in the
development and anatomic organisation of these structures [55].
A murine model of homozygous mutation of the En1 and En2 genes
results in disrupted formation of the mesencephalon and meten-
cephalon, with cerebellar hypoplasia, which mimics the anatomi-
cal ﬁndings in two unrelated infants who were born at term but
died in early infancy from lack of central respiratory drive. It is be-
lieved that these cases resulted from a mutation or deletion in the
En gene [56].
The arcuate nucleus at the ventral surface of the medulla oblon-
gata which aids in the control of central chemoreception, cardio-
ventilatory activity and blood pressure [57], also expresses the
En2 gene. Lavezzi et al. demonstrated high EN2 protein expression
in the arcuate nucleus of the 17th to 22nd gestational week human
foetus, with decreased expression up to the ﬁrst days after birth
[58]. They also studied 13 cases of sudden infant death, wherewithin the EN protein.
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negative EN2 protein expression. Their ﬁndings support the role
of En2 in normal human neuronal development and anatomic
organisation, particularly of the arcuate nucleus.
The only known site of normal adult En2 expression is in the
nervous system, particularly the Purkinje neurones, where immu-
nohistochemical staining identiﬁes it in the nucleus [59,60]. Jan-
kowski et al. showed that gene over-expression resulted in
retardation in the maturation of the Purkinje cells, particularly in
the timed development of their dendritic tree [61]. Owing to its
expression in mesencephalic dopaminergic neurons, Rissling
et al. investigated single-nucleotide polymorphisms (SNPs) in the
promoter region or transcribed part of En2, in individuals with
young-onset Parkinson’s disease (YOPD) [62]. This suggested an
association between SNP rs1345514 and the development of YOPD,
although this has not yet been veriﬁed in an independent sample.
En2 has been linked to the neurodevelopmental disorder, aut-
ism, as it shares the chromosomal region 7q36.3 which is thought
to be an autism susceptibility locus. There appears to be a genetic
linkage in families with autistic members, but also broad similari-
ties between the neuropathology seen in En2 knockout mice and
autistic individuals, including cerebellar hypoplasia, decreased
Purkinje cells and an anterior shift in the position of the amygdala
in the cerebral cortex [63–67]. Further cohort studies, mainly in
Chinese and Indian populations, support this [68–70].
3. Engrailed in cancer
Over-expression of EN2 protein may be linked to tumour devel-
opment in adult humans, particularly in breast, prostate, mela-
noma and ovarian cancers.
En2 has been identiﬁed as a potential oncogene in a breast can-
cer model. Martin et al. identiﬁed ectopic expression of En2 in a
number of breast cancer cell lines but only 7.3% of human breast
cancers [71]. There was no evidence of rearrangement or ampliﬁ-
cation of the gene, so the ectopic expression may result from epi-
genetic modiﬁcation. Non-tumorogenic murine mammary cell
lines were forced to express En2, and subsequently exhibited
malignant characteristics, including a reduction in cell cycling
time, a loss of cell to cell contact and a failure to differentiate in re-
sponse to lactogenic hormones. The cell line induced mammary tu-
mours when transplanted into the cleared mammary glands of
syngeneic hosts. The same group showed that in a human breast
cancer cell line, suppression of En2 resulted in a signiﬁcant de-
crease in their proliferation rate. They did not demonstrate expres-
sion of En2 in normal breast epithelium, and En1 was not
demonstrated in cell lines or human breast tissue.
In the prostate, Bose et al. initially demonstrated En2 over-
expression in human prostate cancer cells as compared to normal
prostate epithelial cells [72]. SiRNA-mediated down-regulation of
En2 in the cell lines resulted in a decrease in PAX-2 expression,
and vice versa, and caused a dramatic decrease in prostate cancer
cell proliferation, as with the previous ﬁndings in breast cancer
cells [71]. Morgan et al. further identiﬁed En2 in prostaticFig. 2. EN2 antigen expression in ovarian cancer. Immunohistochemical analysis of EN
versus normal ovary (E).adenocarcinoma and demonstrated that it is not expressed in nor-
mal prostate tissue, normal tissue adjacent to the cancer, benign
hypertrophy, or high grade prostatic intraepithelial neoplasia, a
pre-malignant lesion [60]. Immunohistochemical staining of pa-
tient tumour biopsies showed that EN2 expression is most intense
in the duct-like structures of tumours, the protein is present in the
cytoplasm, sometimes in the basal membrane, but not in the nu-
cleus. EN2 containing blebs were also identiﬁed in prostatic acini
and ducts, conﬁrming the known secretory properties of EN2. This
group were able to identify EN2 in the urine of 66% of biopsy-
proven prostate cancer patients, some of whom had undetectable
levels of serum prostate speciﬁc antigen (PSA). This contrasted
with <15% positivity in the low PSA control groups, prompting fur-
ther research into its use as a potential biomarker, as discussed la-
ter. In a subsequent cohort of 125 Danish men with conﬁrmed
prostate cancer, 70% were positive for EN2 in their urine [73].
Preliminary work on En2 expression in ovarian cancer has dem-
onstrated high expression in some ovarian cancer cell lines, as well
as in epithelial ovarian cancer tissue [McGrath, S.E. & Michael, A.,
unpublished work]. In a cohort of 118 epithelial ovarian cancer pa-
tients, 88.14% of tumours expressed EN2 whilst all normal ovarian
tissue was negative. No correlation with tumour type, grade and
stage was seen however EN2-expressing mucinous tumours
showed improved overall survival (P = 0.0253). This data was sup-
ported by Immunohistochemical analysis of ovarian cancer tissue
arrays which demonstrated positive EN2 in approximately 80% of
ovarian cancer tissues, compared with low (<10%) or absent
expression in normal tissues (Fig. 2). Analysis of the serum from
67 ovarian cancer patients and 42 age-matched female controls,
showed that 20.9% of the former had antibodies against EN2 com-
pared to 2.4% of the controls. Peptide speciﬁc cytotoxic T-lympho-
cytes were generated by a number of the identiﬁed EN2 epitopes,
which may enable EN2 to be exploited as an immunotherapeutic
target antigen.
Hypermethylation of the engrailed genes has been identiﬁed in
several cancers although its speciﬁc role is yet to be characterised.
Rauch et al. found that all four HOX gene clusters were preferential
targets for DNA methylation in lung cancer cell lines, with addi-
tional hypermethylation of both En1 and En2 [74]. The exact signif-
icance of this is unknown however the authors hypothesised that
such DNA methylation markers could be useful in early diagnosis
of disease. Karpinski et al. determined the methylation status of
three CpG islands at the 2q14.2 chromosomal band, including
En1, in 148 sporadic colorectal cancers [75]. Generally 18% to
25% of sporadic colorectal cancers show CpG island methylator
phenotype (CIMP), and the average number of methylated sites
was signiﬁcantly higher in these tumours, namely 70% En1methyl-
ation was seen in CIMP positive compared with 22% in CIMP neg-
ative tumours. The authors postulate that this hypermethylation,
along with the other CpG islands, may contribute to the speciﬁc
characteristics of CIMP positive tumours and their clinicopatho-
logic features. Of note, these studies did not investigate subsequent
En gene or protein expression. Hypermethylation of En1 has subse-
quently been seen by Mayor et al. in 90% of colorectal tumours2 expression (brown) on four examples of serous papillary adenocarcinoma (A–D)
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hypermethylation, along with other homeobox genes, has been
identiﬁed in the follicular lymphoma cell line, RL, and in ten pri-
mary follicular lymphomas [79]. However transcriptional down-
regulation was not observed, indicating aberrant epigenetic regula-
tion in follicular lymphoma. Although En hypermethylation is pres-
ent in a number of malignancies its functional role is still
unknown, as it does not appear to contribute to gene silencing.
In fact Bell et al. demonstrated EN1 protein over-expression in
cases of adenoid cystic carcinoma (ACC), where signiﬁcant hyper-
methylation of the En1 gene was observed [80]. To date, this is
the only published evidence of EN1 protein over-expression in
malignancy. ACC represents a rare and progressive malignancy of
the salivary glands in which the authors had previously observed
signiﬁcant hypermethylation at the transcriptional start site of
the En1 gene, prompting them to further evaluate EN1 protein
expression [81]. In a cohort of 200 patients, they demonstrated po-
sitive EN1 expression in 58.8% of tubular, 56.5% of cribriform, and
85.7% of the solid histological subtypes. Nuclear staining of the in-
ner ductal cells was observed with only faint expression in the
cytoplasm of salivary ductal cells. The solid pattern was predomi-
nantly poorly differentiated and devoid of myoepithelial cells, sug-
gesting that EN1 expression may correlate with a more aggressive
tumour with poor prognosis. The group mentioned that they had
also performed immunoreactivity on a triple-negative breast carci-
noma microarray, which demonstrated similar results for high-
grade basaloid breast carcinomas.
Table 1 summarises the current evidence linking the Engrailed
genes and their protein products with cancer.
4. Engrailed as a potential biomarker
Several groups have reported the use of homeobox genes as
diagnostic and prognostic biomarkers, as certain gene expression
proﬁles can be linked to tissue speciﬁcity, association with early
stages of carcinogenesis, and even therapy-resistant disease result-
ing in a worse prognosis. The majority of this work has been with
the HOX gene family [82–85], however as more is known about En,
its potential as a biomarker is growing.
There is currently a great deal of interest in the potential of EN2
as a biomarker in prostate cancer. Recent published evidence of its
use as a tumour speciﬁc urinary biomarker for the early diagnosisTable 1
A summary of the evidence linking the Engrailed genes and antigens with cancer.
Evidence for involvement in cancer Cancer type
EN1 over-expression (human tumours) Salivary gland (Adenoid
cystic)
En2 promotes malignant characteristics (murine
mammary cell lines)
Breast
En2 expression required for cancer cell proliferation
(human cell lines)
Breast
Prostate
En2 over-expression (human cell lines & tumours) Breast
Prostate
Ovary
EN2 secretion in urine (human tumours) Prostate
En1 hypermethylation (human cell lines & tumours) Lung
Colorectal
Astrocytoma
Prostate
Salivary gland (Adenoid
cystic)
En2 hypermethylation (human cell lines & tumours) Lung
Follicular lymphomaof prostate cancer, showed that the presence of EN2 in urine was
highly predictive of prostate cancer, with a sensitivity of 66% and
a speciﬁcity of 88.2% [60]. The Prostate Cancer Prevention Trial re-
corded a sensitivity and speciﬁcity of 24% and 93% respectively for
PSA, the current standard detection test for prostate cancer [86].
Hence it is clear that the use of PSA is limited, however it could
be used in combination with urinary EN2 to reduce the need for
prostatic biopsy.
Subsequently, Pandha et al. evaluated the relationship between
levels of pre-treatment urinary EN2 and cancer volume in a Danish
patient cohort who had undergone radical prostatectomy for pros-
tate cancer. Seventy percent of patients were positive for EN2 in
urine and there was a strong relationship between urinary EN2
and prostate cancer volume by linear regression (P = 0.006). Higher
EN2 levels also correlated with advancing tumour stage (P = 0.027).
Notably, no such relationships were observed with serum PSA
however this may reﬂect the small cohort. It was hypothesised that
EN2 may prove a useful diagnostic biomarker in prostate cancer,
but also enable risk stratiﬁcation due to the correlation with tu-
mour volume [73].
Hypermethylation of En1 and En2 has been identiﬁed in several
tumour sites, as previously discussed, and may have potential use
as an early diagnostic marker. Mayor et al. were able to detect
methylated En1 in stool DNA from patients with colorectal carci-
noma with 44% sensitivity and 97% speciﬁcity in patients with cor-
responding tumour methylation [76]. However the sensitivity fell
to 27% when including the 27% of patients whose tumours did
not show En1 methylation. In serum, the sensitivity was only
11%. The authors concluded that the presence of a methylated
En1 CpG island in stool DNA could be developed as a diagnostic
biomarker. En1 was frequently methylated (65%) in primary pros-
tate tumours, signiﬁcantly differentiating cancer from normal tis-
sue when combined with SCTR hypermethylation [78]. Combined
methylation of these two genes may provide potential novel bio-
markers for prostate cancer detection. Bell et al. initially suggested
a potential role for En1 methylation status as a biomarker in hu-
man salivary adenoid cystic carcinoma (ACC), given the correlation
with histologic tumour grade, tumour location and patient out-
come [81]. Subsequently they demonstrated a signiﬁcant correla-
tion between increased EN1 protein expression and a lower
survival rate (P = 0.014) as well as a higher incidence of lymph
node metastasis, suggesting its role as a prognostic biomarker [80].Technique used Reference
Immunohistochemistry [80]
Forced over-expression of En2 [71]
RNAi down-regulation of En2 [71]
RNAi down-regulation of En2 [72]
Semiquantitative RT-PCR
Immunohistochemistry
[71]
Semiquantitative RT-PCR
Immunohistochemistry
[72,60]
Semiquantitative RT-PCR
Immunohistochemistry
McGrath, S.E. & Michael, A.
(unpublished)
ELISA [60,73]
Methylated-CpG island recovery [74]
Methylation-speciﬁc PCR [75,76]
Methylated-CpG island recovery [77]
Methylated-CpG island ampliﬁcation and
microarray
[78]
Methylated CpG island ampliﬁcation and
microarray
[81]
Methylated-CpG island recovery [74]
Methylation-speciﬁc PCR [79]
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The Engrailed sub-family of homeobox genes are essential in
early embryonic development, but have also been identiﬁed in
the normal adult nervous system, as well as in neurodevelopmen-
tal disease. However, the vast majority of En1 or En2 gene expres-
sion in the adult occurs in malignant tissue, particularly in breast,
prostate and ovarian cancers. Methylation studies and identiﬁca-
tion of EN in urine have suggested a role for the gene and its pro-
tein product as potential biomarkers. It is hoped that further work
may conﬁrm associations between En expression and therapy-
resistant, poor prognosis cancers, similar to that identiﬁed with
other homeobox gene proﬁles.
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